arrow
N

Nicolas Poté

Hôpital Bichat
H指数:23
被引数:1,889

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 “DICIPLE” Phase III trial

IFCT-1701“DICIPLE” III期随机试验:晚期非小细胞肺癌患者接受一线纳武利尤单抗联合伊匹木单抗6个月治疗与持续治疗的4年结果

2026-02-120
PRE
Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome

鉴定Pappalysin-2 (PAPP-A2),一种胰岛素样生长因子-1通路调节剂,作为短肠综合征患者 teduglutide 疗效的潜在标志物。

2025-05-140
OA
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
2024-05-012
OAAI
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

欧洲胸部病理学实验室对非小细胞肺癌的真实世界EGFR测试实践

2023-10-0112
OAAI
Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia

血纤维细胞与新型冠状病毒肺炎肺炎严重程度和预后相关

2021-11-0110
OA
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future
2021-02-0111
OAAI
Endocannabinoid Receptor-1 and Sympathetic Nervous System Mediate the Beneficial Metabolic Effects of Gastric Bypass
2020-10-0132
OAAI